Condition
Platinum-Resistant Urothelial Carcinoma
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
100.0%
3 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Terminated3
Clinical Trials (3)
Showing 3 of 3 trials
NCT04936230Phase 2Terminated
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
NCT05052372Terminated
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
NCT04851834Phase 1Terminated
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Showing all 3 trials